Rallybio Corporation - Common Stock — Cash Flow (NASDAQ:RLYB) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -45.53 M-57.28 M-60.27 M-49.28 M-29.81 M -27.59 M Cash from investing activities -2.33 M-112.17 M27.66 M33.49 M47.27 M 54.09 M Cash from financing activities 82.97 M51.08 M143 K5.2 M16 K 19 K Free cash flow -45.53 M-57.28 M-60.27 M-49.28 M-29.81 M -27.59 M

News

Alibaba, Cisco To Report Earnings; Inflation Numbers In Focus

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Rallybio to acquire Candid Therapeutics in $505M deal

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Rallybio (NASDAQ:RLYB)

Lieber, Rallybio CFO, sells $3992 in shares

Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor

Rallybio announces one-for-eight reverse stock split effective Feb 6

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested - TipRanks.com

Rallybio to implement 1-for-8 reverse stock split effective February 6

Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio